vs
Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $11.1M, roughly 1.9× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -84.4%, a 301.0% gap on every dollar of revenue. On growth, NexPoint Real Estate Finance, Inc. posted the faster year-over-year revenue change (-48.8% vs -65.2%).
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
NREF vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $20.6M |
| Net Profit | $24.0M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | — | -106.0% |
| Net Margin | 216.6% | -84.4% |
| Revenue YoY | -48.8% | -65.2% |
| Net Profit YoY | 58.7% | -173.8% |
| EPS (diluted) | $0.47 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | — | ||
| Q3 25 | $12.5M | — | ||
| Q2 25 | $12.1M | — | ||
| Q1 25 | $11.5M | $20.6M | ||
| Q4 24 | $21.7M | $37.4M | ||
| Q3 24 | $12.5M | $19.6M | ||
| Q2 24 | $6.7M | $94.7M | ||
| Q1 24 | $-12.8M | $59.1M |
| Q4 25 | $24.0M | — | ||
| Q3 25 | $50.9M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $26.0M | $-17.3M | ||
| Q4 24 | $15.2M | $1.1M | ||
| Q3 24 | $23.3M | $-14.0M | ||
| Q2 24 | $12.1M | $55.0M | ||
| Q1 24 | $-14.6M | $23.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -106.0% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | 35.7% |
| Q4 25 | 216.6% | — | ||
| Q3 25 | 407.0% | — | ||
| Q2 25 | 184.5% | — | ||
| Q1 25 | 225.6% | -84.4% | ||
| Q4 24 | 69.9% | 3.0% | ||
| Q3 24 | 186.4% | -71.7% | ||
| Q2 24 | 179.7% | 58.1% | ||
| Q1 24 | 114.3% | 39.7% |
| Q4 25 | $0.47 | — | ||
| Q3 25 | $1.14 | — | ||
| Q2 25 | $0.54 | — | ||
| Q1 25 | $0.70 | $-0.42 | ||
| Q4 24 | $0.71 | $-0.20 | ||
| Q3 24 | $0.74 | $-0.35 | ||
| Q2 24 | $0.40 | $1.55 | ||
| Q1 24 | $-0.83 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.1M | $67.8M |
| Total DebtLower is stronger | $771.2M | — |
| Stockholders' EquityBook value | $388.0M | $417.3M |
| Total Assets | $5.3B | $486.5M |
| Debt / EquityLower = less leverage | 1.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | — | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $19.2M | $67.8M | ||
| Q4 24 | $3.9M | $101.2M | ||
| Q3 24 | $34.7M | $78.0M | ||
| Q2 24 | $4.3M | $185.3M | ||
| Q1 24 | $13.5M | $68.4M |
| Q4 25 | $771.2M | — | ||
| Q3 25 | $720.9M | — | ||
| Q2 25 | $815.6M | — | ||
| Q1 25 | $831.5M | — | ||
| Q4 24 | $799.3M | — | ||
| Q3 24 | $815.5M | — | ||
| Q2 24 | $861.0M | — | ||
| Q1 24 | $843.3M | — |
| Q4 25 | $388.0M | — | ||
| Q3 25 | $375.4M | — | ||
| Q2 25 | $348.2M | — | ||
| Q1 25 | $343.7M | $417.3M | ||
| Q4 24 | $336.5M | $428.7M | ||
| Q3 24 | $335.8M | $422.4M | ||
| Q2 24 | $327.5M | $429.9M | ||
| Q1 24 | $327.1M | $269.4M |
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | $486.5M | ||
| Q4 24 | $5.4B | $526.3M | ||
| Q3 24 | $5.7B | $554.6M | ||
| Q2 24 | $6.6B | $582.0M | ||
| Q1 24 | $7.1B | $510.8M |
| Q4 25 | 1.99× | — | ||
| Q3 25 | 1.92× | — | ||
| Q2 25 | 2.34× | — | ||
| Q1 25 | 2.42× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 2.63× | — | ||
| Q1 24 | 2.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.5M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | -0.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.5M | — | ||
| Q3 25 | $8.1M | — | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $16.0M | $-38.5M | ||
| Q4 24 | $4.4M | $-31.6M | ||
| Q3 24 | $14.7M | $-24.3M | ||
| Q2 24 | $-7.5M | $39.8M | ||
| Q1 24 | $17.7M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | -0.19× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | -27.94× | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | -0.62× | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
